People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ekso Bionics Holdings, Inc. | — | Biotechnology | Series C | $112.0M | $113.4M | 2014 |
Frank Moreman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank Moreman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Max Scheder-Bieschin | 1 | 3 |
| Nathan Harding | 1 | 3 |
| Marilyn Hamilton | 1 | 2 |
| Thomas Looby | 1 | 2 |
| Steven Sherman | 1 | 2 |
| Jack Peurach | 1 | 2 |
| Russ Angold | 1 | 2 |
| Thomas F. Schreck | 1 | 1 |
| Jason F. Jones | 1 | 1 |
| Charles F. Li | 1 | 1 |
| Daniel Boren | 1 | 1 |
| John F. Glenn | 1 | 1 |
| Marilyn F. Hamilton | 1 | 1 |
| William F. Shaw | 1 | 1 |
| Stanley F. Stern | 1 | 1 |
| Ted F. Wang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.